Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Povidone-Iodine for Preventing White Spots During Orthodontic Treatment
NCT06616207Phase 2Active, not recruiting
- Sponsor
- University of Washington
- Start
- Sep 2024
- Primary completion
- Mar 2027
- Modality
- Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, triple-blind trial of IVIEW-1502 in White spot lesion (WSL), gingivitis and Gingival bleeding (2 arms), sponsored by University of Washington. Primary endpoint: Percentage of patients with at least one new white spot lesion at 12 months. Started Sep 2024; status: active, not recruiting.
02
Drugs
IVIEW-1502
03
Conditions
White spot lesion (WSL)gingivitisGingival bleeding
Beyond the preview
Go deeper on NCT06616207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06616207.